Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors

Vivax malaria remains one of the most serious and neglected tropical diseases, with 132 to 391 million clinical cases per year and 2.5 billion people at risk of infection. A vaccine against Plasmodium vivax could have more impact than any other intervention, and the use of a vaccine targeting multip...

Descripción completa

Detalles Bibliográficos
Autores principales: Atcheson, Erwan, Bauza, Karolis, Salman, Ahmed M., Alves, Eduardo, Blight, Joshua, Viveros-Sandoval, Martha Eva, Janse, Chris J., Khan, Shahid M., Hill, Adrian V. S., Reyes-Sandoval, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Microbial Immunity and Vaccines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105880/
https://www.ncbi.nlm.nih.gov/pubmed/29986894
http://dx.doi.org/10.1128/IAI.00114-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105880/
https://www.ncbi.nlm.nih.gov/pubmed/29986894
http://dx.doi.org/10.1128/IAI.00114-18

Ejemplares similares